(S)-5-oxo-1-phenyl-pyrrolidine-2-carboxylic acid | 1001390-58-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-5-oxo-1-phenyl-pyrrolidine-2-carboxylic acid
• 英文别名: 5-Oxo-1-phenylproline；(2S)-5-oxo-1-phenylpyrrolidine-2-carboxylic acid
• CAS: 1001390-58-4
• 化学式: C₁₁H₁₁NO₃
• 分子量: 205.213
• InChiKey: JITXFZOGKNNXCT-VIFPVBQESA-N

物化性质

• 沸点：
  494.6±38.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-5-oxo-1-phenyl-pyrrolidine-2-carboxylic acid 在 磷酸二苄酯 、 silver(I) acetate 、 palladium diacetate 、 氯甲酸乙酯 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 26.0h， 生成
  参考文献：
  名称：

  立体定向钯催化焦谷氨酸衍生物在C3位置上的C–H芳基化反应，该位置由8-氨基喹啉作为指导基团

  摘要：

  描述了一种高效且立体定向的钯催化焦谷氨酸衍生物的CH芳基化反应的方案，该方案使用8-氨基喹啉作为导向基团。已表明，使用带有不同官能团的各种芳基和杂芳基碘化物可以有效地进行反应，从而以高至高收率得到C3芳基化的顺式产物。从这些C–H芳基化产物中除去8-氨基喹啉单元可以使用合成上有用的基于顺式和反式焦谷氨酸的结构单元。

  DOI：

  10.1021/acs.orglett.7b01776
• 作为产物：
  描述：

  5-oxo-1-phenylproline methyl ester 在 甲醇 、 水 、 sodium hydroxide 作用下， 生成 (S)-5-oxo-1-phenyl-pyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  Discovery and structure–activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor

  摘要：

  A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X(7) receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and compound 31 was identified as a potent P2X(7) antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clinical studies. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.033

文献信息

• DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES
  申请人：Kasai Shizuo

  公开号：US20120071489A1

  公开（公告）日：2012-03-22

  The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.

  本发明涉及一种化合物，其化学式如下所示，其中每个符号如本说明书中所定义，该化合物具有优越的降低RBP4作用，并且可用作预防或治疗由RBP4增加介导的疾病或病况的药物组合物。
• Novel Receptor Antagonists and Their Methods of Use
  申请人：Chambers J. Laura

  公开号：US20080009541A1

  公开（公告）日：2008-01-10

  The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.

  本发明涉及一种新型的氧代脯氨酰胺衍生物，其化学式为（I），可以调节P2X7受体功能，并能够拮抗P2X7受体上ATP的作用，以及利用这些化合物或其药物组合物治疗由P2X7受体介导的疾病，例如疼痛、炎症和神经退行性疾病。
• Receptor antagonists and their methods of use
  申请人：Glaxo Group Limited

  公开号：US08048907B2

  公开（公告）日：2011-11-01

  The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.

  本发明涉及式（I）的新型氧代脯氨酰胺衍生物，其调节P2X7受体功能并能够拮抗P2X7受体上ATP的作用，以及使用这种化合物或其药物组合物治疗由P2X7受体介导的疾病，例如疼痛、炎症和神经退行性疾病。
• Pyrrolidine Compounds Which Modulate The CB2 Receptor
  申请人：Berry Angela

  公开号：US20120142677A1

  公开（公告）日：2012-06-07

  Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. (I)

  本发明揭示了调节CB2受体的化合物。本发明的化合物结合并激动CB2受体，并且可用于治疗炎症。那些是激动剂的化合物还可用于治疗疼痛。 (I)
• Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
  申请人：Kasai Shizuo

  公开号：US08853215B2

  公开（公告）日：2014-10-07

  The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.

  本发明涉及一种化合物，其表示为式中每个符号如本说明书中所定义，该化合物具有优异的RBP4降低作用，并可作为药物组合物用于预防或治疗由RBP4增加介导的疾病或病状。